Sirna, Nucleonics, CytRx Adjust Drug Timelines; Alnylam Adds to Its Pipeline | GenomeWeb

Four RNAi-based therapeutics developers provided additional information about their product-development efforts over the past two weeks, with one • Alnylam Pharmaceuticals • announcing the addition of a new drug program, and three • Sirna Therapeutics, Nucleonics, and CytRx • pushing back previously announced timelines.

RNAi News has provided a breakdown of the updates.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.